Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Stock Information for QXO Inc Com Par Value $0.00001 (New)
Loading
Please wait while we load your information from QuoteMedia.